Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CoVIg 19

Next Previous
Drug Profile

CoVIg 19

Alternative Names: anti-coronavirus hIVIG - Takeda; Anti-coronavirus hyperimmune intravenous immunoglobulin - Takeda; Anti-COVID-19 Hyperimmune Globulin - Takeda; Anti-SARS-CoV-2 polyclonal H-IG - Takeda; Anti-SARS-CoV-2 polyclonal hyperimmune globulin - Takeda; COVID-19 H-IG - Takeda; CoVIg-19; TAK-888

Latest Information Update: 27 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer Takeda; University of Minnesota
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 25 Apr 2022 Biotest AG has been acquired by Grifols
  • 21 May 2021 University of Minnesota completes a phase III ITAC trial in the treatment of COVID-2019 infections in the US, Greece, UK, Denmark, Japan, Germany, Indonesia, Israel, Argentina, Nigeria and Spain (NCT04546581)
  • 08 Oct 2020 Phase-III clinical trials in COVID-2019 infections in Denmark, Japan, Germany, Nigeria, Spain (IV) (EudraCT2020-002542-16) (NCT04546581)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top